Miriam M Triyatni

US Patent:

20120100574, Apr 26, 2012

Filed:

Sep 28, 2009

Appl. No.:

13/122154

Inventors:

Bertrand Saunier - Versailles, FR
Miriam Triyatni - Montclair NJ, US
Edward A. Berger - Rockville MD, US

International Classification:

C12P 21/02
C12N 7/02
C12N 7/00
C12N 5/10
C07K 14/18

US Classification:

435 691, 435325, 530350, 4352351, 435239

Abstract:

Provided herein is a mammalian cell transformed to contain a plasmid encoding a T7 or SP6 promoter operably linked to one or more HCV genes, a subgenomic replicon from a flavivirus and a cytoplasmic T7 and SP6 RNA amplification system. Also provided herein are isolated replication-competent HCV particles produced by the method comprising the steps of providing a transformed mammalian cell according to the first embodiment, culturing the cell, and recovering the replication-competent HCV particles from the cell culture. Provided herein are isolated HCV structural proteins produced by the method comprising the steps of providing a transformed mammalian cell according to the first embodiment, culturing the cell, and recovering the HCV structural proteins from the cell culture. Further provided herein is a system for assaying HCV entry into a cell comprising a first plasmid encoding a T7 or SP6 promoter operably linked to an HCV polynucleotide comprising at least the 5′-UTR to NS2 operably linked to an EMCV IRES in frame with an SP6 or T7 polymerase gene, respectively, a first host cell line expressing a replicon from a flavivirus and comprising a cytoplasmic T7 and SP6 RNA amplification system, a second plasmid encoding a reporter gene operably linked to both T7 and SP6 promoters in tandem, and a second host cell line comprising a cytoplasmic T7 polymerase or SP6 polymerase RNA amplification system.

US Patent:

20050272029, Dec 8, 2005

Filed:

Aug 18, 2003

Appl. No.:

10/524443

Inventors:

Bertrand Saunier - Bethesda MD, US
Miriam Triyatni - Bethesda MD, US

International Classification:

C12Q001/70
C12Q001/68

US Classification:

435005000, 435006000, 435239000

Abstract:

Methods for obtaining HCV complexes and HCV-like particles comprising HCV structural genes are provided. In one method, cells containing HCV-like particles are lysed with digitonin in the presence of protease inhibitors. Polyethylene glycol is slowly added to the lysate, to provide a precipitate that comprises complexes of the HCV structural proteins associated with lipid vesicles or micelles and complexes comprising viral structural proteins in the form of insoluble aggregates. In another method, the lysate is centrifuged through a sucrose cushion. Preferably, the pellet is then subjected to equilibrium ultracentrifugation, to provide a preparation of HCV-like particles that are heterogenous in size. The third method comprises subjecting the infected cells to hypertonic/hypotonic shock, and lysing the cells with digitonin in the presence of protease inhibitors. The lysate is pelleted and fractionated to provide a population of HCV-like particles that are substantially homogenous and have an average diameter of about 50 nm. As used herein the term “substantially homogenous” means that the shape of the particles are similar and that the size of the particles vary by 10% or less. Methods of using the HCV complexes and HCV-Iike particles as screening tools, diagnostic tools, and immunogenic compositions are also provided. Methods of treating patients exhibiting symptoms of HCV infection with compounds or substances that interfere with binding or internalization of the present HCV-like particles to asialoglycoprotein receptors are also provided.

US Patent:

20150197726, Jul 16, 2015

Filed:

Mar 12, 2014

Appl. No.:

14/205893

Inventors:

- Nutley NJ, US
Matthew Michael Hamilton - Hackettstown NJ, US
Sei Kameoka - Montclair NJ, US
Brian Leonard - Weehawken NJ, US
Miriam Triyatni - Montclair NJ, US

International Classification:

C12N 5/071
C07D 401/04

Abstract:

The invention relates to the compounds of formula I and pharmaceutically acceptable salts and esters thereof, wherein R-Rare as defined in the description and claims. In addition, the present invention relates to methods of manufacturing and using the compounds of formula I as well as pharmaceutical compositions containing such compounds. The compounds of formula I are useful in differentiating stem cells into more mature or adult-like hepatocytes for use as drug screening platforms and in disease modeling applications.

US Patent:

20150158840, Jun 11, 2015

Filed:

Feb 3, 2015

Appl. No.:

14/612893

Inventors:

- Nutley NJ, US
Matthew Michael Hamilton - Hackettstown NJ, US
Sei Kameoka - Cambridge MA, US
Brian Leonard - Weehawken NJ, US
Miriam Triyatni - Montclair NJ, US

International Classification:

C07D 401/04

Abstract:

The invention relates to the compounds of formula I and pharmaceutically acceptable salts and esters thereof, wherein R-Rare as defined in the description and claims. In addition, the present invention relates to methods of manufacturing and using the compounds of formula I as well as pharmaceutical compositions containing such compounds. The compounds of formula I are useful in differentiating stem cells into more mature or adult-like hepatocytes for use as drug screening platforms and in disease modeling applications.